BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 16316614)

  • 1. Parenteral iron therapy: a single institution's experience over a 5-year period.
    Laman CA; Silverstein SB; Rodgers GM
    J Natl Compr Canc Netw; 2005 Nov; 3(6):791-5. PubMed ID: 16316614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parenteral iron therapy options.
    Silverstein SB; Rodgers GM
    Am J Hematol; 2004 May; 76(1):74-8. PubMed ID: 15114602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parenteral iron use in the management of anemia in end-stage renal disease patients.
    Bailie GR; Johnson CA; Mason NA
    Am J Kidney Dis; 2000 Jan; 35(1):1-12. PubMed ID: 10620537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
    Auerbach M; Al Talib K
    Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The comparative safety of intravenous iron dextran, iron saccharate, and sodium ferric gluconate.
    Fishbane S; Kowalski EA
    Semin Dial; 2000; 13(6):381-4. PubMed ID: 11130261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
    Faich G; Strobos J
    Am J Kidney Dis; 1999 Mar; 33(3):464-70. PubMed ID: 10070910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.
    Michael B; Coyne DW; Fishbane S; Folkert V; Lynn R; Nissenson AR; Agarwal R; Eschbach JW; Fadem SZ; Trout JR; Strobos J; Warnock DG;
    Kidney Int; 2002 May; 61(5):1830-9. PubMed ID: 11967034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative safety of various intravenous iron preparations in chronic kidney disease patients.
    Anirban G; Kohli HS; Jha V; Gupta KL; Sakhuja V
    Ren Fail; 2008; 30(6):629-38. PubMed ID: 18661414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative rates of adverse events with different formulations of intravenous iron.
    Okam MM; Mandell E; Hevelone N; Wentz R; Ross A; Abel GA
    Am J Hematol; 2012 Nov; 87(11):E123-4. PubMed ID: 22965928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Use of Parenteral Iron Therapy for the Treatment of Postpartum Anemia.
    Nash CM; Allen VM
    J Obstet Gynaecol Can; 2015 May; 37(5):439-442. PubMed ID: 26168105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experience with a large dose (500 mg) of intravenous iron dextran and iron saccharate in peritoneal dialysis patients.
    Prakash S; Walele A; Dimkovic N; Bargman J; Vas S; Oreopoulos D
    Perit Dial Int; 2001; 21(3):290-5. PubMed ID: 11475345
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute injury with intravenous iron and concerns regarding long-term safety.
    Bishu K; Agarwal R
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safe administration of iron sucrose in a patient with a previous hypersensitivity reaction to ferric gluconate.
    Sane R; Baribeault D; Rosenberg CL
    Pharmacotherapy; 2007 Apr; 27(4):613-5. PubMed ID: 17381390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Parenteral iron replacement].
    Cynke E
    Praxis (Bern 1994); 1997 May; 86(20):835-6. PubMed ID: 9312810
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products.
    Wang C; Graham DJ; Kane RC; Xie D; Wernecke M; Levenson M; MaCurdy TE; Houstoun M; Ryan Q; Wong S; Mott K; Sheu TC; Limb S; Worrall C; Kelman JA; Reichman ME
    JAMA; 2015 Nov; 314(19):2062-8. PubMed ID: 26575062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Importance of the different i.v. iron generations for everyday medical practice].
    Biggar P; Hahn KM
    MMW Fortschr Med; 2013 Mar; 155 Suppl 1():18-24. PubMed ID: 23678667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety profiles of total dose infusion of low-molecular-weight iron dextran and high-dose iron sucrose in renal patients.
    Atalay H; Solak Y; Acar K; Govec N; Turk S
    Hemodial Int; 2011 Jul; 15(3):374-8. PubMed ID: 21564503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
    Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
    J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis.
    Fishbane S; Wagner J
    Am J Kidney Dis; 2001 May; 37(5):879-83. PubMed ID: 11325667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicity of parenteral iron dextran therapy.
    Burns DL; Pomposelli JJ
    Kidney Int Suppl; 1999 Mar; 69():S119-24. PubMed ID: 10084295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.